Clinical Trial Update: Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial of upfront maintenance olaparib in advanced BRCA wild-type ovarian cancer with homologous recombination deficiency has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Alexander B Olawaiye, MD | Conditions: Ovarian Cancer | Phase 2 | Status: WITHDRAWN